Irma Egoavil – Country Manager, Celgene Mexico
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Celgene is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, and ISTODAX. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Contact details
Celgene México
Juan Salvador Agraz 65, Piso 17,
Colonia Lomas de Santa Fe.
C.P. 05300. México, D.F.
MEXICO
Tel: +52 (55) 41236700
Website: www.celgene.com
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Luisa Gutierrez, CEO at Medisi, explains the importance of helping get fast registration for high quality medtech products registrations and explains Medisi’s integral solutions for both the regulation and distribution…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
Zurich Pharma was created with the vision of becoming a leader in the oncology segment at the international level. General manager and founder, Orlando Silva Fernandéz, discusses how state-of-the-art technology…
President and CEO of Grupo ENESA, Jaime Chico Pardo breaks down the private capital fund’s core investment pillars—centered on active management and driving long-term value—while elaborating on the flourishing opportunities…
Roberto Tapia-Conyer, General Director at the Carlos Slim Foundation, explains the unique position of the Foundation to develop and introduce innovation that could create breakthroughs in the National Healthcare System…
Cecilia Calderón, general director at Vigpharma, highlights how the national pharmacovigilance and technovigilance regulations have been evolving during the last five years as well as showcasing the added value of…
Joel Osorio, CEO & Founder Alejandro De La Parra, Co-Founder & Chief Operating Officer Alexa Jeppi, Co-Founder, RegenerAge Beauty & Health Ira Pastor, Board Member …
Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the…
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s…
Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping…
The founder and managing partner of the LatAm-based consultancy Oriundo, Paul Doulton discusses the company’s unique value offering—comprising both industry veterans and global associates to propel business development—while highlighting Mexico…
See our Cookie Privacy Policy Here
